Phase II Study of the Targeted Mutant IDH2 Inhibitor Enasidenib in Combination With Azacitidine for Relapsed/Refractory AML
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Enasidenib (Primary)
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia
- Focus Therapeutic Use
- 19 Nov 2018 Planned End Date changed from 30 Sep 2021 to 20 Sep 2021.
- 19 Nov 2018 Planned primary completion date changed from 30 Sep 2021 to 20 Sep 2021.
- 19 Nov 2018 Status changed from not yet recruiting to recruiting.